Evidence map›Paper›PMID 35771570›Full record

ArticleBiotechnology journal2022

Regeneration of Capto Core 700 resin through high throughput and laboratory scale studies and impact on production of a SARS-CoV-2 vaccine candidate.

Spyridon Konstantinidis, Seth R Reinhart, Christine Castagna, Murphy R Poplyk, Richard R Rustandi, Kristen L Flor, Jillian Acevedo-Skrip, Rachel Thompson, Christopher J Wang, Sheng-Ching Wang and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Biotechnology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Spyridon KonstantinidisVaccine Process Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.ORCID https://orcid.org/0000-0001-7227-5853
Seth R ReinhartVaccine Process Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.
Christine CastagnaVaccine Process Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.
Murphy R PoplykVaccine Process Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.
Richard R RustandiVaccine Analytical Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.
Kristen L FlorInvestigative Pathology, MRL, Merck & Co., Inc., Rahway, New Jersey, USA.
Jillian Acevedo-SkripVaccine Analytical Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.
Rachel ThompsonVaccine Analytical Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.
Christopher J WangVaccine Analytical Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.
Sheng-Ching WangVaccine Process Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.
Michael A WintersVaccine Process Research & Development, Merck & Co., Inc., Rahway, New Jersey, USA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the development of a SARS-CoV-2 vaccine candidate, at the height of the COVID-19 pandemic, raw materials shortages, including chromatography resins, necessitated the determination of a cleaning in place (CIP) strategy for a multimodal core-shell resin both rapidly and efficiently. Here, the deployment of high throughput (HT) techniques to screen CIP conditions for cleaning Capto Core 700 resin exposed to clarified cell culture harvest (CCCH) of a SARS-CoV-2 vaccine candidate produced in Vero adherent cell culture are described. The best performing conditions, comprised of 30% n-propanol and ≥0.75 N NaOH, were deployed in cycling experiments, completed with miniature chromatography columns, to demonstrate their effectiveness. The success of the CIP strategy was ultimately verified at the laboratory scale. Here, its impact was assessed across the entire purification process which also included an ultrafiltration/diafiltration step. It is shown that the implementation of the CIP strategy enabled the re-use of the Capto Core 700 resin for up to 10 cycles without any negative impact on the purified product. Hence, the strategic combination of HT and laboratory-scale experiments can lead rapidly to robust CIP procedures, even for a challenging to clean resin, and thus help to overcome supply shortages.

Indexed as

COVID-19COVID-19 Vaccines1-PropanolHumansPandemicsRegenerationSARS-CoV-2Sodium Hydroxide1-PropanolCOVID-19 VaccinesSodium HydroxideCapto CorechromatographyCIPhigh throughputlive virus vaccineRoboColumnsscale-up

Identifiers

PMID35771570
PMCPMC9353343
OpenAlexW4283738164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.